Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

Payment Information We accept all major credit cards

By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.
RETURN TO HOME
$599
Basal Insulin, GLP-1RA, Other

Novo Nordisk Q3 ’22 Earnings Update; FY Guidance Raised

Here is a brief preview of this blast: Novo Nordisk hosted its Q3 ’22 earnings call (press release; slides) and announced an increase to its 2022 financial guidance. During the call, management provided updates across its business, including the semaglutide global supply constraints as well as the high-dose oral sema and new QW oral sema development projects. Additionally, Novo disclosed it has terminated development of its oral PCSK9i and LA-GDF15 development programs. Of note, the Q&A portion of the call was terminated early due to technical difficulties. Below, FENIX provides highlights and insights from the call.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.